文献速递垂体与肾上腺疾病

泼尼松龙与氢化可的松治疗肾上腺功能不全的死亡率风险:回顾性队列研究

Mortality Risk in Patients With Adrenal Insufficiency Using Prednisolone or Hydrocortisone: A Retrospective Cohort Study.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

总体调整后风险比相似(泼尼松龙1.76 vs 氢化可的松1.69,P=0.65),但原发性肾上腺功能不全中泼尼松龙组死亡率更高(HR 2.92 vs 1.90,P=0.0020)。

要点

  • 总体肾上腺功能不全患者中,泼尼松龙与氢化可的松的调整后死亡率风险相似。
  • 原发性肾上腺功能不全中,泼尼松龙治疗者死亡率显著高于氢化可的松。
  • 泼尼松龙组患者年龄更大且合并症更多,但调整后死亡率升高仍持续。

核心结论

  • 在原发性但非继发性肾上腺功能不全中,泼尼松龙治疗与更高的死亡率相关。

研究设计与样本

  • 观察性回顾性队列研究,使用英国初级保健数据库(Clinical Practice Research Datalink)数据。

主要发现

  • 总体调整后风险比:泼尼松龙1.76(95%CI 1.54-2.01),氢化可的松1.69(95%CI 1.57-1.82),P=0.65。
  • 继发性肾上腺功能不全中两种治疗的风险比相似。
  • 原发性肾上腺功能不全中,泼尼松龙组调整后HR为2.92(95%CI 2.19-3.91),氢化可的松组为1.90(95%CI 1.66-2.16),P=0.0020。

临床怎么用

  • 原发性肾上腺功能不全患者使用泼尼松龙替代治疗时需警惕死亡率升高风险。
  • 继发性肾上腺功能不全中泼尼松龙与氢化可的松的死亡率风险相似。

局限性

  • 泼尼松龙治疗患者数量较少。
  • 泼尼松龙组患者具有更多危险因素(年龄更大、合并自身免疫病和恶性肿瘤更多、盐皮质激素替代更少)。
  • 需要进一步证据评估泼尼松龙作为常规替代治疗的长期安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Prednisolone has been recommended rather than hydrocortisone for glucocorticoid replacement in adrenal insufficiency due its longer duration of action and lower cost. OBJECTIVE: To determine mortality rates with prednisolone versus hydrocortisone. METHODS: In this observational study, we used data extracted from a UK primary care database (Clinical Practice Research Datalink) to measure the relative mortality of patients with primary and secondary adrenal insufficiency, who were treated with either prednisolone or hydrocortisone, and control individuals who were individually matched for age, sex, period, and place of follow-up. RESULTS: As expected, mortality in adrenal insufficiency irrespective of cause was increased, based on 5478 patients (4228 on hydrocortisone; 1250 on prednisolone) and 54 314 controls (41 934 and 12 380, respectively). Overall, the adjusted hazard ratio (HR) was similar with the 2 treatments (prednisolone, 1.76 [95% CI, 1.54-2.01] vs hydrocortisone 1.69 [1.57-1.82]; P = 0.65). This was also the case for secondary adrenal insufficiency. In primary disease (1405 on hydrocortisone vs 137 on prednisolone; 13 965 and 1347 controls, respectively), prednisolone users were older, more likely to have another autoimmune disease and malignancy, and less likely to have mineralocorticoid replacement. Nevertheless, after adjustment, the HR for prednisolone-treated patients remained higher than for those taking hydrocortisone (2.92 [2.19-3.91] vs 1.90 [1.66-2.16]; P = 0.0020). CONCLUSION: In primary but not in secondary adrenal insufficiency, mortality was higher with prednisolone. The study was large, but the number of prednisolone-treated patients was small, and they had greater risk factors. Nonetheless, the increased mortality associated with prednisolone persisted despite statistical adjustment. Further evidence is needed regarding the long-term safety of prednisolone as routine replacement.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Ngaosuwan K, Johnston DG, Godsland IF, et al. Mortality Risk in Patients With Adrenal Insufficiency Using Prednisolone or Hydrocortisone: A Retrospective Cohort Study. J Clin Endocrinol Metab. 2021. PMID: 33993277. doi:10.1210/clinem/dgab347

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。